Novartis setzt im 1. Quartal die starke operative Performance fort, bestätigt derzeit die Prognose 2020 und fördert verschiedenste Aktivitäten, um globale Massnahmen gegen COVID-19 zu unterstützen

NEXT STORY
New 6-year data for Roche’s OCREVUS (ocrelizumab) show earlier treatment initiation nearly halves risk of needing walking aid in relapsing multiple sclerosis
PREV STORY
Cromos Pharma Supports R-Pharm in Initiation of a Global Program to Test Two of its Leading Candidates in Patients with Severe COVID-19 Infection. First Patients Have Been Recruited
Subscribe now to PM360
Get in touch with PM360 Experts On Call

Experts on Call

Ads

You May Also Like

Arcutis Biotherapeutics Showcases New Roflumilast Data in Psoriasis and Seborrheic Dermatitis at American Academy of Dermatology (AAD) Virtual Meeting Experience (VMX) 2021

author_avatar
NASDAQ Market News

ADMA Biologics Opens Its Newest ADMA BioCenters Plasma Collection Facility

author_avatar
NASDAQ Market News

Sanofi: Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with chronic rhinosinusitis with nasal polyps

Dupixent® (dupilumab) showed positive topline results in two Phase 3 trials of patients with ...

author_avatar
NASDAQ Market News